Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Covington
US Department of Justice
Baxter
Chubb
Cipla
UBS
Daiichi Sankyo
McKinsey

Generated: May 23, 2018

DrugPatentWatch Database Preview

Bausch And Lomb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for BAUSCH AND LOMB INC, and when can generic versions of BAUSCH AND LOMB INC drugs launch?

BAUSCH AND LOMB INC has six approved drugs.

There are four US patents protecting BAUSCH AND LOMB INC drugs.

There are seventy-four patent family members on BAUSCH AND LOMB INC drugs in twenty-two countries and eight supplementary protection certificates in five countries.

Summary for Bausch And Lomb Inc
International Patents:74
US Patents:4
Tradenames:7
Ingredients:6
NDAs:6
Drug Master File Entries: 1

Drugs and US Patents for Bausch And Lomb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes 6,780,877 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bausch And Lomb Inc XIBROM bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 021664-001 Mar 24, 2005 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 RX Yes Yes 8,784,789 ➤ Try a Free Trial Y ➤ Try a Free Trial
Bausch And Lomb Inc IPRATROPIUM BROMIDE ipratropium bromide SOLUTION;INHALATION 075835-001 Oct 15, 2001 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bausch And Lomb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc LOTEMAX loteprednol etabonate GEL;OPHTHALMIC 202872-001 Sep 28, 2012 5,800,807 ➤ Try a Free Trial
Bausch And Lomb Inc XIBROM bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 021664-001 Mar 24, 2005 4,910,225 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09

Non-Orange Book US Patents for Bausch And Lomb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,765,758 Compositions and methods for eye whitening ➤ Try a Free Trial
8,080,550 Anesthetic compositions and methods of use ➤ Try a Free Trial
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same ➤ Try a Free Trial
8,580,787 Compositions and methods for reducing activation of alpha-1 receptors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bausch And Lomb Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0031 France ➤ Try a Free Trial PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/11/692/001 DU 20110518; REGISTRATION NO/DATE AT EEC: EU/1/11/692/001 DU 20110518
C0056 France ➤ Try a Free Trial PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
00494 Netherlands ➤ Try a Free Trial PRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
462 Luxembourg ➤ Try a Free Trial PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chinese Patent Office
Fuji
Express Scripts
US Army
Colorcon
Accenture
Deloitte
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.